RxDoctor Payments Data

Amir Malik, MD

Interventional Cardiology · Fort Worth, TXNPI 1568413417

Payments from drug & device makers

$184,750in general payments, 2019–2025

Across 422 payments — averaging $437.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$117K
  • Medtronic$31K
  • Shockwave Medical, Inc$18K
  • Idev Technologies, Inc.$8K
  • Abbott$2K
  • Boehringer Ingelheim$1K
  • plus $8K from 41 others
$70in research payments, 2019–2025

Across 1 payment — averaging $70.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$70

What the payments were for

  • Consulting fees$100,63874%
  • Speaking & faculty fees$5,5004%
  • Travel & lodging$6,3425%
  • Food & beverage$15,80512%
  • Education$530%
  • Ownership interest$7,7666%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$184,750 in reported general payments places this provider in the 85th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$924,109
Medicare patients
792
Services billed
4,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban373$317,604
EntrestoSacubitril/Valsartan132$117,037
Repatha SureclickEvolocumab73$77,035
BrilintaTicagrelor115$76,281
FarxigaDapagliflozin Propanediol50$49,750
XareltoRivaroxaban64$47,949
MultaqDronedarone Hcl35$37,644
JardianceEmpagliflozin17$9,614
Praluent PenAlirocumab15$8,888
DapagliflozinDapagliflozin Propanediol15$6,675
Metoprolol Succinate386$5,790
ClopidogrelClopidogrel Bisulfate561$5,738
VascepaIcosapent Ethyl14$4,725
Prasugrel Hcl40$2,378
Losartan Potassium175$2,306

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$119$317,604373 claims
AstraZenecaBrilinta, Farxiga$824$126,030165 claims
NovartisEntresto$210$117,037132 claims
Johnson & JohnsonXarelto$14$47,94964 claims
Sanofi-aventis U.S. LLCMultaq$119$37,64435 claims
Boehringer IngelheimJardiance$1,368$9,61417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →